# Daratumumab in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma and Severe Renal Impairment

> **NCT02977494** · PHASE2 · COMPLETED · sponsor: **Universitätsklinikum Hamburg-Eppendorf** · enrollment: 22 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Daratumumab
- **DRUG:** Bortezomib
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT02977494
- **Lead sponsor:** Universitätsklinikum Hamburg-Eppendorf
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06
- **Primary completion:** 2021-06
- **Final completion:** 2021-06
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2022-05-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02977494

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02977494, "Daratumumab in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma and Severe Renal Impairment". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02977494. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*